60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
60 Degrees Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $1.11M, up 73.2% year over year. For fiscal 2025 it was $1.01M, up 65.5% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | +65.5% |
| FY2024 | Dec 31, 2024 | $607.57K | +139.6% |
| FY2023 | Dec 31, 2023 | $253.57K | +13.6% |
| FY2022 | Dec 31, 2022 | $223.21K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $207.90K | +106.0% |
| Q1 FY2026 | Mar 31, 2026 | $162.09K | -0.9% |
| Q4 FY2025 | Dec 31, 2025 | $303.39K | +25.6% |
| Q3 FY2025 | Sep 30, 2025 | $437.60K | +223.4% |
| Q2 FY2025 | Jun 30, 2025 | $100.93K | -19.2% |
| Q1 FY2025 | Mar 31, 2025 | $163.55K | +54.8% |
| Q4 FY2024 | Dec 31, 2024 | $241.64K | +92.3% |
| Q3 FY2024 | Sep 30, 2024 | $135.29K | +164.3% |
| Q2 FY2024 | Jun 30, 2024 | $124.97K | +109.9% |
| Q1 FY2024 | Mar 31, 2024 | $105.67K | +515.4% |
| Q4 FY2023 | Dec 31, 2023 | $125.68K | -25.3% |
| Q3 FY2023 | Sep 30, 2023 | $51.19K | +13.3% |
| Q2 FY2023 | Jun 30, 2023 | $59.53K | – |
| Q1 FY2023 | Mar 31, 2023 | $17.17K | – |
| Q3 FY2022 | Sep 30, 2022 | $168.19K | – |
| Q2 FY2022 | Jun 30, 2022 | $45.17K | – |